Compared to Estimates, Pacira (PCRX) Q4 Earnings: A Look at Key Metrics

For the quarter ended December 2025, Pacira (PCRX) reported revenue of $196.87 million, up 5.1% over the same period last year. EPS came in at $0.57, compared to $0.91 in the year-ago quarter.

The reported revenue compares to the Zacks Consensus Estimate of $196.99 million, representing a surprise of -0.06%. The company delivered an EPS surprise of -32.74%, with the consensus EPS estimate being $0.85.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how Pacira performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Revenue- Total net product sales: $196.87 million versus $199.23 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +5.1% change.
• Revenue- Net product sales- ZILRETTA: $32.98 million compared to the $34.39 million average estimate based on three analysts. The reported number represents a change of -0.4% year over year.
• Revenue- Net product sales- Bupivacaine liposome injectable suspension: $1.11 million compared to the $1.82 million average estimate based on three analysts.
• Revenue- Net product sales- EXPAREL: $155.78 million compared to the $154.58 million average estimate based on three analysts. The reported number represents a change of +5.5% year over year.
• Revenue- Net product sales- iovera: $7 million versus the three-analyst average estimate of $7.32 million. The reported number represents a year-over-year change of +8.5%.

View all Key Company Metrics for Pacira here>>>

Shares of Pacira have returned +15.1% over the past month versus the Zacks S&P 500 composite's +0.6% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

 
Pacira BioSciences, Inc. (PCRX): Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research